Sanofi (ETR:SNW)
93.33
-0.07 (-0.07%)
Apr 24, 2025, 5:35 PM CET
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€544,970
Profits / Employee
€76,003
Market Cap
114.13B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Merck KGaA | 59,020 |
Siemens Healthineers AG | 72,000 |
Fresenius SE & Co. KGaA | 176,486 |
Bayer Aktiengesellschaft | 90,587 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 111,513 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 23,412 |
Sanofi News
- 1 day ago - Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs - Reuters
- 1 day ago - Innate Pharma Regains Its Rights on CD123 Targeting ANKET and Announces Sanofi’s Intention to Make a Strategic Investment in the Company - Wallstreet:Online
- 6 days ago - Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Reuters
- 6 days ago - Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - GlobeNewsWire
- 7 days ago - Earendil Labs and Sanofi partner for two bispecific antibodies - Seeking Alpha
- 8 days ago - Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study - Benzinga
- 9 days ago - Sanofi flunks mid-stage trial for asthma drug - Seeking Alpha
- 9 days ago - Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD - Benzinga